Zepbound for Sleep Apnea: What the Evidence Shows
⚡ Key Clinical Takeaways
- Zepbound is the brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist.
- The approval was based on the SURMOUNT-OSA trials, which studied tirzepatide in adults with OSA and obesity, with and without CPAP.
- A clinician may consider tirzepatide for an adult with:
- The most common side effects are nausea, vomiting, diarrhea, constipation and abdominal discomfort.
- Zepbound does not replace a sleep study.
Quick answer: Tirzepatide (Zepbound) was approved by the FDA in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, used alongside a reduced-calorie diet and exercise. In the SURMOUNT-OSA trial it reduced the apnea-hypopnea index substantially, but it is not a substitute for diagnosis, CPAP when indicated, or long-term follow-up.
Weight loss has long been recommended for obstructive sleep apnea, but "lose weight" is easier said than done. Tirzepatide changes the conversation because it produces substantial, sustained weight loss in many people and has now been studied as a treatment for OSA itself.
That does not mean everyone with sleep apnea should ask for a prescription. The medication has a specific indication, real side effects and a cost that can be prohibitive.
What Zepbound is
Zepbound is the brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist. It is given as a once-weekly injection. It is also marketed as Mounjaro for type 2 diabetes. The two brands contain the same active ingredient but have different approved indications and dosing schedules.
The FDA approval for OSA specifies adults with moderate-to-severe obstructive sleep apnea and obesity (BMI ≥30), used with a reduced-calorie diet and increased physical activity. It is not approved for central sleep apnea, and it is not a treatment for insomnia or simple snoring.
What the trial showed
The approval was based on the SURMOUNT-OSA trials, which studied tirzepatide in adults with OSA and obesity, with and without CPAP. The primary measure was the change in the apnea-hypopnea index (AHI), the number of breathing events per hour.
Participants receiving tirzepatide had a substantial reduction in AHI compared with placebo, along with meaningful weight loss. Some participants no longer met the criteria for moderate-to-severe OSA. The results are encouraging, but they are average effects from a clinical trial, not a guarantee for an individual.
The trial also measured sleep-related symptoms and inflammation markers. The medication is not a cure for apnea; it reduces the severity in many patients, and weight can return if the medication is stopped.
Who may be a candidate
A clinician may consider tirzepatide for an adult with:
- Moderate-to-severe obstructive sleep apnea diagnosed by a sleep study
- Obesity (BMI ≥30)
- A commitment to diet and activity changes
- No contraindication to GLP-1/GIP therapy
It is not a first step for mild OSA, and it is not a replacement for CPAP in someone who is symptomatic or has severe oxygen desaturation. The medication takes time to work; CPAP may still be needed in the interim.
People with a personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis, severe gastroparesis, gallbladder disease or pregnancy should discuss risks carefully. The medication is not recommended during pregnancy.
Side effects and practical realities
The most common side effects are nausea, vomiting, diarrhea, constipation and abdominal discomfort. They often improve as the dose is increased slowly, but not always. Serious risks include pancreatitis, gallbladder disease, dehydration, kidney injury and, rarely, bowel obstruction. The label carries a boxed warning about thyroid C-cell tumors observed in rodents.
The injection is weekly, and the dose is titrated over months. It is expensive, and insurance coverage varies. Some plans cover it for OSA with prior authorization; others do not. Without coverage, the out-of-pocket cost can be very high.
What it does not replace
Zepbound does not replace a sleep study. You need a diagnosis and a baseline severity measurement. It does not replace CPAP for everyone; a person with severe OSA or significant daytime sleepiness may need CPAP while the medication takes effect, and some will need it long term.
It does not replace follow-up. A repeat sleep study or home test may be needed to see whether the AHI has improved enough to change treatment. It does not replace treatment of central apnea, which has different causes and risks.
Questions to ask your clinician
- Do I have obstructive or central sleep apnea, and how severe is it?
- Am I a candidate for tirzepatide based on my BMI and other conditions?
- What will we use to measure response, and when?
- Do I need to keep using CPAP during treatment?
- What side effects should make me call immediately?
- Is the medication covered, and what is the plan if it is not?
The bottom line
Tirzepatide is a real advance for a subset of patients with OSA and obesity. It is not a shortcut around sleep testing, CPAP when indicated, or lifestyle support. The best candidates are patients who have a confirmed diagnosis, a clear weight-related treatment goal and a clinician who will monitor both the sleep apnea and the metabolic effects.
If you need to arrange testing, find a sleep study near you or find a sleep doctor.
Frequently Asked Questions
Is Zepbound approved for sleep apnea?
Yes, for adults with moderate-to-severe obstructive sleep apnea and obesity (BMI ≥30), used with a reduced-calorie diet and exercise. It is not approved for central sleep apnea.
Does Zepbound cure sleep apnea?
No. It can substantially reduce the apnea-hypopnea index and improve symptoms in many patients, but it is not a cure. Weight and apnea can return if treatment stops, and some patients still need CPAP.
How much weight do you need to lose for sleep apnea to improve?
There is no single threshold. Even modest weight loss can help some people, while others need more. The response is individual, and the sleep study is the best way to measure it.
Can I stop CPAP if I start Zepbound?
Only with your clinician's guidance and a repeat assessment. Do not stop CPAP on your own, especially if you have severe apnea, daytime sleepiness or oxygen desaturation.
Is Zepbound covered by insurance for OSA?
Coverage varies. Some plans cover it with prior authorization and documentation of OSA and obesity; others exclude weight-loss medications. Check your plan and ask the prescriber's office for help with authorization.
Final Thoughts
Zepbound is not a miracle for sleep apnea; it is a well-studied weight-loss medication with a specific role in OSA. It works best when the diagnosis is confirmed, the treatment plan is measured and CPAP is not abandoned prematurely. Ask for the trial data, the follow-up plan and the cost before you start.
This article is general information, not medical advice. Discuss any medication with a qualified clinician.
Related reading
Ready to find an accredited sleep clinic near you?
Browse 7,246 verified sleep centers (4,975 AASM accredited), filter by tests and treatments, and reach out directly — all in one verified directory.
🔍 Search Accredited Centersor call a clinic directly from its profile — every listing has a verified phone number.
This medical guide complies with the American Academy of Sleep Medicine (AASM) standards of care for sleep disorders and reflects generally accepted clinical guidelines. It is informational and not a substitute for personalized medical advice.